Merck (NYSE:MRK) announced on Thursday that its Phase 3 KEYNOTE-B96 trial for its anti-PD-1 therapy Keytruda reached the ...
In early October 2025, Merck announced FDA approval for a subcutaneous version of Keytruda and shared positive Phase 3 trial ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-B96 trial, ...
Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring ...
Moderna has shared some of the phase 1/2 data that persuaded it to expand and p | Moderna has shared some of the phase 1/2 ...
The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...
TipRanks on MSN
Moderna sees 5-year follow up from Phase 2 study in 2026
Moderna (MRNA) shares dropped 4.2% to $25.99 on Friday afternoon after the company provided an update on mRNA-4359 plus pembrolizumab at an ...
Hamlin was given the treatment as part of a clinical trial after receiving a diagnosis of melanoma last year. She recently ...
Wall Street analysts expect the subcutaneous version of Keytruda, which just launched last week, to help soften the blow when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback